Merus (NASDAQ:MRUS - Free Report) - Equities research analysts at Leerink Partnrs decreased their FY2024 earnings estimates for Merus in a research note issued on Wednesday, April 24th. Leerink Partnrs analyst A. Berens now forecasts that the biotechnology company will earn ($3.66) per share for the year, down from their previous forecast of ($3.54). The consensus estimate for Merus' current full-year earnings is ($3.31) per share. Leerink Partnrs also issued estimates for Merus' Q4 2024 earnings at ($1.09) EPS, FY2025 earnings at ($4.16) EPS and FY2026 earnings at ($0.84) EPS.
A number of other research analysts also recently commented on MRUS. StockNews.com downgraded Merus from a "hold" rating to a "sell" rating in a research note on Monday, March 4th. HC Wainwright raised their price objective on Merus from $48.00 to $65.00 and gave the company a "buy" rating in a report on Thursday, February 29th. William Blair restated an "outperform" rating on shares of Merus in a report on Monday, April 22nd. BMO Capital Markets upped their price target on shares of Merus from $49.00 to $58.00 and gave the company an "outperform" rating in a research report on Thursday, February 29th. Finally, Truist Financial started coverage on shares of Merus in a report on Thursday, March 28th. They set a "buy" rating and a $69.00 price target on the stock. One research analyst has rated the stock with a sell rating and eleven have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $56.33.
Read Our Latest Report on MRUS
Merus Trading Up 0.2 %
NASDAQ MRUS traded up $0.07 during midday trading on Monday, hitting $45.11. The company had a trading volume of 975,944 shares, compared to its average volume of 599,798. The firm has a 50-day moving average price of $45.02 and a 200-day moving average price of $34.17. The company has a market capitalization of $2.65 billion, a PE ratio of -14.84 and a beta of 1.10. Merus has a twelve month low of $18.21 and a twelve month high of $52.03.
Merus (NASDAQ:MRUS - Get Free Report) last released its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.38). Merus had a negative net margin of 352.56% and a negative return on equity of 50.61%. The business had revenue of $8.94 million during the quarter, compared to analyst estimates of $10.43 million.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the stock. AE Wealth Management LLC raised its position in Merus by 14.2% in the 3rd quarter. AE Wealth Management LLC now owns 22,500 shares of the biotechnology company's stock valued at $531,000 after buying an additional 2,801 shares during the last quarter. BluePath Capital Management LLC purchased a new stake in shares of Merus in the third quarter valued at about $33,000. China Universal Asset Management Co. Ltd. grew its position in Merus by 142.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,477 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 867 shares in the last quarter. Teacher Retirement System of Texas grew its position in Merus by 47.9% in the 3rd quarter. Teacher Retirement System of Texas now owns 12,084 shares of the biotechnology company's stock worth $285,000 after purchasing an additional 3,916 shares in the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its stake in Merus by 10.8% in the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 13,446 shares of the biotechnology company's stock valued at $317,000 after buying an additional 1,310 shares during the last quarter. Institutional investors own 96.14% of the company's stock.
About Merus
(
Get Free Report)
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
Further Reading
Before you consider Merus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merus wasn't on the list.
While Merus currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
